#United States #Koning Health #Vera Scan #Norcross #3D imaging

Koning Health Secures Series C Funding to Revolutionize Breast Imaging

Koning Health, a trailblazer in medical imaging technologies, has announced the launch of its official Series C funding round in collaboration with Sage Tap Poder Special Purpose Vehicle (SPV). This significant financial movement is specifically targeted towards boosting its innovative breast imaging solution, the Vera Scan. The funding aims to expand the availability and adoption of this groundbreaking technology within the healthcare industry, particularly in breast imaging.

The financial round is structured under Rule 506(c) of Regulation D, allowing only accredited and verified investors to participate. Matthew Stack, CFO of Koning Health, emphasizes that this funding round is a vital step in transforming breast imaging. "We are dedicated to providing women with a more accurate, comfortable, and accessible alternative to traditional mammography," Stack stated. This alignment with Sage Tap Poder represents a commitment to achieving these objectives during a pivotal phase of Koning's commercial expansion.

The Vera Scan stands as the first and only FDA-approved 3D breast imaging system specifically designed for diagnostic purposes. Unlike traditional mammograms, which often require painful breast compression, the Vera Scan offers a swift, comfortable, and patient-friendly experience. It captures detailed 360-degree images of breast tissue in a mere seven seconds per breast, making it exceptionally suitable for dense tissue and effective in calcification detection.

The newly raised capital is expected to expedite the deployment of the Vera Scan in clinics and hospitals across the United States, push for reimbursement strategies, facilitate adoption among radiologists and spur ongoing innovations in 3D imaging technologies. Kirk Honour, Managing Partner at Sage Tap Poder, expressed confidence in Koning's mission. "We are proud to support a company redefining women’s health through groundbreaking imaging technology. This opportunity offers accredited investors a chance to engage with a category-defining medical device company that possesses strong commercial traction and a clear growth path," Honour remarked.

Koning Health envisions a future where comprehensive breast imaging is accessible and not synonymous with discomfort. By leveraging advanced computed tomography technology, they aim to enhance the way clinicians visualize and assess breast tissue. Furthermore, investments from this Series C round will directly benefit the optimization of early disease detection, diagnosis, and subsequent intervention.

As Koning Health enters this new chapter, their commitment to innovation in the imaging sector continues to set them apart. For anyone interested in participating in this offering, Kirk Honour is available for consultation at 888-558-5228 x803. For further insights and updates about Koning's initiatives, potential investors are encouraged to visit their official website.

The implications of this funding extend beyond just financial prospects; it highlights a significant shift towards prioritizing patient comfort and accurate diagnostics in women's health. By bridging the gap between technology and healthcare, Koning Health is poised to lead the charge in modern medical imaging.